Clinical lab sellers do not usually need another account list. They need a way to decide which accounts deserve work now.
This article is about one account type: clinicaltest labs and diagnostic lab accounts. It is most useful for teams selling diagnostic-use products, lab equipment, software, services, logistics, revenue-cycle support, staffing, or commercial tools into clinical laboperations. It is less useful for teams focused only on research-use settings.
Goal: turn public lab movement into a small set ofaccounts that a rep can research, call, route to marketing, or ignore with aclear reason.
That last part matters. The goal is not more names. The goalis a better starting point for field work.
The Practical Problem
When I started building LabProspects, the hard part was notfinding public lab data. The hard part was turning public lab data intosomething a sales or business development team could use.
Lab names vary. Addresses move. Certificate language can bemisunderstood. A new record can be a real commercial opportunity, a smalladministrative update, a low-fit point-of-care site, or noise. If you send allof it to a rep, the list gets ignored.
That is the failure mode: treating every signal as a lead.
A signal is not a lead. A signal is a reason to investigate.
What counts as a clinical lab expansion signal?
For clinical and diagnostic lab accounts, useful signals can include:
- a new lab appearing in public laboratory records
- a new location tied to a health system, specialty practice, physician group, diagnostics company, or reference lab
- a certificate application, certificate change,or testing-complexity clue
- a change in address, lab director, ownership, or organizational affiliation
- a new specialty, test menu clue, job posting, facility announcement, or service-line change
CLIA records are often a useful starting point for U.S. clinical labs because CLIA applies to laboratory testing on human specimens for health assessment, diagnosis, prevention, or treatment. Labs also need the appropriate certificate before they accept human samples for testing. That does not make the record a sales-ready opportunity. It makes it a structured clue.
Where to look first
Start with sources that can be checked by another person. Use this source stack:
- Official lab records: CLIA lookup, CMS laboratory registry material, state lab licensing sources where relevant.
- Organization context: lab website, health-system site, specialty-practice site, location pages, accreditation pages, and press releases.
- Operating clues: job postings, service-line language, test-menu pages, lab director or management clues, and public business records.
- Territory context: existing customers, target account definitions, rep coverage, travel patterns, and current campaign focus.
For every signal, capture five fields:
- source
- date checked
- what changed
- why it may matter commercially
- next action
If you cannot fill those fields, you probably do not have a usable signal yet.
The workflow: signal -> verify -> filter -> action
Define the account type before pulling data
A molecular diagnostics vendor, a point-of-care manufacturer, a LIMS company, a courier service, and a revenue-cycle vendor should not score the same lab the same way.
Write the account type in operational language:
- moderate- or high-complexity clinical labs in a defined geography
- physician office labs doing waived testing
- hospital outreach labs adding locations
- specialty practices with in-office testing activity
- independent labs with evidence of service-line growth
Find the observable change
Do not ask, "Is this a good account?" first. Ask,"What changed?"
A new CLIA entry, address update, certificate clue, specialty clue, hiring pattern, or affiliation change is the raw event. Write it down plainly.
Example: "New clinical lab record in Raleigh, tied to a specialty practice, certificate information reviewed on June 23, 2026, website shows patient testing language."
That is better than:
"New lab lead."
Verify that the signal is real enough to use
Before routing anything to sales, check whether the lab appears active, whether the address is a real operating site, whether the name matches the organization context, and whether the certificate or complexity clue fits.
Filter for commercial fit
Use a simple fit test:
- Does this lab match the product's real use case?
- Is the setting relevant: hospital, independent lab, physician office lab, reference lab, specialty practice, or outreach site?
- Does the certificate or testing-complexity clue support the likely workflow?
- Is there a reachable buyer, influencer, or operational owner?
- Is there a timing reason to act now?
If the answer is weak, do not force the account into the call plan. Put it into nurture, hold it for later review, or discard it.
Assign the next action
Every reviewed signal should end in one of four actions:
- Research: the account may be relevant, but buyer, specialty, or operating context is unclear
- Sales action: the account matches the offer and has a timing reason to engage
- Marketing nurture: the account fits the market but does not justify immediate rep time.
- Ignore: the signal is real, but it does not fit the offer.
Practical examples
A new waived-testing site may matter to a point-of-care manufacturer, but it may not matter to a company selling tools for high-complexity molecular workflows.
A certificate or complexity change may matter to a vendor selling instruments, validation support, quality software, staffing, accreditation support, or workflow services. The next step is to verify what testing appears connected to the lab and who likely owns the operational decision.
A new address tied to a health system might be a true expansion, a relocation, or only a billing/admin update. Verify before outreach. The sales action changes depending on which one it is.
A job posting for medical laboratory scientists, molecular technologists, accessioning staff, or lab operations roles can strengthen the signal when it lines up with a new or changing lab record. It should not stand alone.
What to measure
Measure quality, not just volume.
Useful metrics include:
- number of new or changed labs reviewed by territory
- percentage that match the target account definition
- time from signal detection to first appropriate action
- false-positive rate by signal type
- meetings or qualified conversations by signal type
- accounts moved to nurture with a clear reason
The goal is not to replace experienced sales judgment. The goal is to give that judgment a cleaner input.
The useful end state
At the end of the process, the work product should be a small account queue, not a giant market map.
Each account should have:
- lab name
- location
- signal
- source and date checked
- fit reason
- owner
- next action
- review date
That is the artifact a sales manager can review. Clinical lab expansion signals are useful when they help teams make better field decisions: which accounts to research, which territories need attention, which campaigns should narrow their focus, and which conversations have a reason to happen now.
Used carefully, the value is not more names. The value is better timing, less noise, and a more defensible reason to spend time on one account before another.
Nathan Harrington is the founder of LabProspects, a platform focused on helping life-science commercial teams identify new and changing laboratory accounts. His work centers on making lab-market data useful forterritory planning, account prioritization, and practical sales workflows without requiring a heavy enterprise CRM process.
.webp)
